Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (370)	12/29/1997 11:13:00 PM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

<<The FDA move wasn't so hard to predict.>> Two points: 1) We knew that the Paxene application was a NDA and that the FDA panel was not satisfied with the information Ivax provided. Ivax had to prove that Paxene was a different drug and a Better drug. Why didn't the FDA ask for more information? Can Ivax file an amendment with new information? 2) Today must have been a buy-on-the-bad-news day. The selling in NPRO seems completely overdone. At about $30 million in capitalization it would be cheaper for Ivax to buy them out than pay any royalties on the international sales. Everybody knew that Paxene was doomed. This was foolish panic selling. Jackson